person · Reporting owner

Pereira Brian JG

Disclosed activity across 3 companies

Tapewire entity: 21262
SEC CIK: 0001298146

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ABEONA THERAPEUTICS INC.ABEO · Entity 5808	Director · Executive Chairman	April 15, 2020	April 17, 2020
PROKIDNEY CORP.PROK · Entity 5181	Director	August 18, 2026	August 20, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ABEONA THERAPEUTICS INC.

Report date April 15, 2020 · Filed April 17, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.50 · Expires 2030-04-15	Direct	930,000	Reported balance After 2020-04-15 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-04-15 · Grant · Acquired 930,000 · Balance 930,000 F1: The options will vest 25% on April 15, 2021, and in 36 equal monthly installments thereafter.

Filing footnotes · ownership attribution and instrument terms

F1: The options will vest 25% on April 15, 2021, and in 36 equal monthly installments thereafter.

PROKIDNEY CORP.

Report date August 18, 2026 · Filed August 20, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	IndirectBy Brian J. G. Pereira 2012 Irrevocable Trust	445,897	Reported balance After 2026-08-18 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2026-08-18 · Sale · Disposed 229,338 · Balance 445,897 F1: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.345 to $1.40, inclusive. The reporting person undertakes to provide to ProKidney Corp., any security holder of ProKidney Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Class A Common StockSEC Table I · non-derivative	IndirectBy Brian J. G. Pereira 2012 Irrevocable Trust	222,948	Reported balance After 2026-08-19 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2026-08-19 · Sale · Disposed 222,949 · Balance 222,948 F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.38 to $1.50, inclusive. The reporting person undertakes to provide to ProKidney Corp., any security holder of ProKidney Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Class A Common StockSEC Table I · non-derivative	IndirectBy Brian J. G. Pereira 2012 Irrevocable Trust	0	Reported balance After 2026-08-20 transaction · row 5 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 5 · 2026-08-20 · Sale · Disposed 222,948 · Balance 0 F3: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.38 to $1.47, inclusive. The reporting person undertakes to provide to ProKidney Corp., any security holder of ProKidney Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Class A Common StockSEC Table I · non-derivative	Direct	0	Ending reported balance After 2026-08-20 transaction · row 6 3 source rows · reconciled sequence Row 2 · 2026-08-18 · Sale · Disposed 27,826 · Balance 54,103 F1: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.345 to $1.40, inclusive. The reporting person undertakes to provide to ProKidney Corp., any security holder of ProKidney Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 4 · 2026-08-19 · Sale · Disposed 27,051 · Balance 27,052 F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.38 to $1.50, inclusive. The reporting person undertakes to provide to ProKidney Corp., any security holder of ProKidney Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 6 · 2026-08-20 · Sale · Disposed 27,052 · Balance 0 F3: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.38 to $1.47, inclusive. The reporting person undertakes to provide to ProKidney Corp., any security holder of ProKidney Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.345 to $1.40, inclusive. The reporting person undertakes to provide to ProKidney Corp., any security holder of ProKidney Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.38 to $1.50, inclusive. The reporting person undertakes to provide to ProKidney Corp., any security holder of ProKidney Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.38 to $1.47, inclusive. The reporting person undertakes to provide to ProKidney Corp., any security holder of ProKidney Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

KalVista Pharmaceuticals, Inc.

Report date June 11, 2026 · Filed June 11, 2026

Section 16 reporting ended · disclosed 2026-06-11. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.95 · Expires 2029-01-31	Direct	Reported balance After 2026-06-11 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-11 · Disposition to issuer · Disposed 14,000 · Balance 0 F1: The securities were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2026 (the "Merger Agreement"), by and among KalVista Pharmaceuticals, Inc., a Delaware corporation (the "Issuer" or the "Company"), Chiesi Farmaceutici S.p.A., an Italian societa per azioni ("Parent"), and Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Company Common Stock"), for a price per share of $27.00 (the "Merger Consideration"), without interest, less any applicable tax withholding. Effective as of June 11, 2026, Merger Sub merged with and into the Company with the Company surviving the Merger as a wholly owned subsidiary of the Parent (the "Merger"). F3: Pursuant to the terms of the Merger Agreement, each option to purchase shares of Company Common Stock ("Company Option") that was outstanding and unexercised immediately prior to the effective time of the Merger (the "Effective Time") and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and converted into the right of the holder thereof to receive a cash payment (without interest) equal to the product of (A) the excess of (x) the Merger Consideration over (y) the per share exercise price of such Company Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time. Each Company Option that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration payable in respect thereof. F2: The option is fully vested.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.88 · Expires 2030-09-30	Direct	Reported balance After 2026-06-11 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-11 · Disposition to issuer · Disposed 7,000 · Balance 0 F1: The securities were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2026 (the "Merger Agreement"), by and among KalVista Pharmaceuticals, Inc., a Delaware corporation (the "Issuer" or the "Company"), Chiesi Farmaceutici S.p.A., an Italian societa per azioni ("Parent"), and Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Company Common Stock"), for a price per share of $27.00 (the "Merger Consideration"), without interest, less any applicable tax withholding. Effective as of June 11, 2026, Merger Sub merged with and into the Company with the Company surviving the Merger as a wholly owned subsidiary of the Parent (the "Merger"). F3: Pursuant to the terms of the Merger Agreement, each option to purchase shares of Company Common Stock ("Company Option") that was outstanding and unexercised immediately prior to the effective time of the Merger (the "Effective Time") and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and converted into the right of the holder thereof to receive a cash payment (without interest) equal to the product of (A) the excess of (x) the Merger Consideration over (y) the per share exercise price of such Company Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time. Each Company Option that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration payable in respect thereof. F2: The option is fully vested.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.45 · Expires 2031-09-29	Direct	Reported balance After 2026-06-11 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-06-11 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: The securities were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2026 (the "Merger Agreement"), by and among KalVista Pharmaceuticals, Inc., a Delaware corporation (the "Issuer" or the "Company"), Chiesi Farmaceutici S.p.A., an Italian societa per azioni ("Parent"), and Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Company Common Stock"), for a price per share of $27.00 (the "Merger Consideration"), without interest, less any applicable tax withholding. Effective as of June 11, 2026, Merger Sub merged with and into the Company with the Company surviving the Merger as a wholly owned subsidiary of the Parent (the "Merger"). F3: Pursuant to the terms of the Merger Agreement, each option to purchase shares of Company Common Stock ("Company Option") that was outstanding and unexercised immediately prior to the effective time of the Merger (the "Effective Time") and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and converted into the right of the holder thereof to receive a cash payment (without interest) equal to the product of (A) the excess of (x) the Merger Consideration over (y) the per share exercise price of such Company Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time. Each Company Option that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration payable in respect thereof. F2: The option is fully vested.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.53 · Expires 2032-10-12	Direct	Reported balance After 2026-06-11 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-06-11 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: The securities were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2026 (the "Merger Agreement"), by and among KalVista Pharmaceuticals, Inc., a Delaware corporation (the "Issuer" or the "Company"), Chiesi Farmaceutici S.p.A., an Italian societa per azioni ("Parent"), and Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Company Common Stock"), for a price per share of $27.00 (the "Merger Consideration"), without interest, less any applicable tax withholding. Effective as of June 11, 2026, Merger Sub merged with and into the Company with the Company surviving the Merger as a wholly owned subsidiary of the Parent (the "Merger"). F3: Pursuant to the terms of the Merger Agreement, each option to purchase shares of Company Common Stock ("Company Option") that was outstanding and unexercised immediately prior to the effective time of the Merger (the "Effective Time") and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and converted into the right of the holder thereof to receive a cash payment (without interest) equal to the product of (A) the excess of (x) the Merger Consideration over (y) the per share exercise price of such Company Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time. Each Company Option that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration payable in respect thereof. F2: The option is fully vested.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.08 · Expires 2033-09-25	Direct	Reported balance After 2026-06-11 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-06-11 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: The securities were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2026 (the "Merger Agreement"), by and among KalVista Pharmaceuticals, Inc., a Delaware corporation (the "Issuer" or the "Company"), Chiesi Farmaceutici S.p.A., an Italian societa per azioni ("Parent"), and Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Company Common Stock"), for a price per share of $27.00 (the "Merger Consideration"), without interest, less any applicable tax withholding. Effective as of June 11, 2026, Merger Sub merged with and into the Company with the Company surviving the Merger as a wholly owned subsidiary of the Parent (the "Merger"). F3: Pursuant to the terms of the Merger Agreement, each option to purchase shares of Company Common Stock ("Company Option") that was outstanding and unexercised immediately prior to the effective time of the Merger (the "Effective Time") and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and converted into the right of the holder thereof to receive a cash payment (without interest) equal to the product of (A) the excess of (x) the Merger Consideration over (y) the per share exercise price of such Company Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time. Each Company Option that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration payable in respect thereof. F2: The option is fully vested.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.54 · Expires 2034-10-02	Direct	Reported balance After 2026-06-11 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-06-11 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: The securities were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2026 (the "Merger Agreement"), by and among KalVista Pharmaceuticals, Inc., a Delaware corporation (the "Issuer" or the "Company"), Chiesi Farmaceutici S.p.A., an Italian societa per azioni ("Parent"), and Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Company Common Stock"), for a price per share of $27.00 (the "Merger Consideration"), without interest, less any applicable tax withholding. Effective as of June 11, 2026, Merger Sub merged with and into the Company with the Company surviving the Merger as a wholly owned subsidiary of the Parent (the "Merger"). F3: Pursuant to the terms of the Merger Agreement, each option to purchase shares of Company Common Stock ("Company Option") that was outstanding and unexercised immediately prior to the effective time of the Merger (the "Effective Time") and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and converted into the right of the holder thereof to receive a cash payment (without interest) equal to the product of (A) the excess of (x) the Merger Consideration over (y) the per share exercise price of such Company Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time. Each Company Option that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration payable in respect thereof. F2: The option is fully vested.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.05 · Expires 2035-09-30	Direct	Reported balance After 2026-06-11 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2026-06-11 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: The securities were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2026 (the "Merger Agreement"), by and among KalVista Pharmaceuticals, Inc., a Delaware corporation (the "Issuer" or the "Company"), Chiesi Farmaceutici S.p.A., an Italian societa per azioni ("Parent"), and Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Company Common Stock"), for a price per share of $27.00 (the "Merger Consideration"), without interest, less any applicable tax withholding. Effective as of June 11, 2026, Merger Sub merged with and into the Company with the Company surviving the Merger as a wholly owned subsidiary of the Parent (the "Merger"). F3: Pursuant to the terms of the Merger Agreement, each option to purchase shares of Company Common Stock ("Company Option") that was outstanding and unexercised immediately prior to the effective time of the Merger (the "Effective Time") and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and converted into the right of the holder thereof to receive a cash payment (without interest) equal to the product of (A) the excess of (x) the Merger Consideration over (y) the per share exercise price of such Company Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time. Each Company Option that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration payable in respect thereof. F4: The option vests over a 12 month period: 1/12th on November 1, 2025, after which 1/12th of the total shares vest monthly, subject to continued service through each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The securities were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2026 (the "Merger Agreement"), by and among KalVista Pharmaceuticals, Inc., a Delaware corporation (the "Issuer" or the "Company"), Chiesi Farmaceutici S.p.A., an Italian societa per azioni ("Parent"), and Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Company Common Stock"), for a price per share of $27.00 (the "Merger Consideration"), without interest, less any applicable tax withholding. Effective as of June 11, 2026, Merger Sub merged with and into the Company with the Company surviving the Merger as a wholly owned subsidiary of the Parent (the "Merger").

F2: The option is fully vested.

F3: Pursuant to the terms of the Merger Agreement, each option to purchase shares of Company Common Stock ("Company Option") that was outstanding and unexercised immediately prior to the effective time of the Merger (the "Effective Time") and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and converted into the right of the holder thereof to receive a cash payment (without interest) equal to the product of (A) the excess of (x) the Merger Consideration over (y) the per share exercise price of such Company Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time. Each Company Option that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration payable in respect thereof.

F4: The option vests over a 12 month period: 1/12th on November 1, 2025, after which 1/12th of the total shares vest monthly, subject to continued service through each vesting date.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 20, 2026 Filed Aug 20, 2026 21:00 UTC	PROKIDNEY CORP. PROK · Entity 5181	SaleClass A Common Stock	27,052	$1.42	$38,411.13	Disclosure SEC source: 0001193125-26-359349 · ownership.xml · nonDerivative · entry 6 Pereira Brian JG · CIK 0001298146 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.38 to $1.47, inclusive. The reporting person undertakes to provide to ProKidney Corp., any security holder of ProKidney Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
August 20, 2026 Filed Aug 20, 2026 21:00 UTC	PROKIDNEY CORP. PROK · Entity 5181	SaleClass A Common Stock	222,948	$1.42	$316,563.87	Disclosure SEC source: 0001193125-26-359349 · ownership.xml · nonDerivative · entry 5 Pereira Brian JG · CIK 0001298146 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Brian J. G. Pereira 2012 Irrevocable Trust Disclosed balance after: 0 F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.38 to $1.47, inclusive. The reporting person undertakes to provide to ProKidney Corp., any security holder of ProKidney Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
August 19, 2026 Filed Aug 20, 2026 21:00 UTC	PROKIDNEY CORP. PROK · Entity 5181	SaleClass A Common Stock	27,051	$1.44	$38,972.38	Disclosure SEC source: 0001193125-26-359349 · ownership.xml · nonDerivative · entry 4 Pereira Brian JG · CIK 0001298146 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,052 F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.38 to $1.50, inclusive. The reporting person undertakes to provide to ProKidney Corp., any security holder of ProKidney Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
August 19, 2026 Filed Aug 20, 2026 21:00 UTC	PROKIDNEY CORP. PROK · Entity 5181	SaleClass A Common Stock	222,949	$1.44	$321,202.62	Disclosure SEC source: 0001193125-26-359349 · ownership.xml · nonDerivative · entry 3 Pereira Brian JG · CIK 0001298146 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Brian J. G. Pereira 2012 Irrevocable Trust Disclosed balance after: 222,948 F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.38 to $1.50, inclusive. The reporting person undertakes to provide to ProKidney Corp., any security holder of ProKidney Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
August 18, 2026 Filed Aug 20, 2026 21:00 UTC	PROKIDNEY CORP. PROK · Entity 5181	SaleClass A Common Stock	27,826	$1.37	$38,155.01	Disclosure SEC source: 0001193125-26-359349 · ownership.xml · nonDerivative · entry 2 Pereira Brian JG · CIK 0001298146 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,103 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.345 to $1.40, inclusive. The reporting person undertakes to provide to ProKidney Corp., any security holder of ProKidney Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
August 18, 2026 Filed Aug 20, 2026 21:00 UTC	PROKIDNEY CORP. PROK · Entity 5181	SaleClass A Common Stock	229,338	$1.37	$314,468.27	Disclosure SEC source: 0001193125-26-359349 · ownership.xml · nonDerivative · entry 1 Pereira Brian JG · CIK 0001298146 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Brian J. G. Pereira 2012 Irrevocable Trust Disclosed balance after: 445,897 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.345 to $1.40, inclusive. The reporting person undertakes to provide to ProKidney Corp., any security holder of ProKidney Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
August 04, 2026 Filed Aug 6, 2026 12:09 UTC	PROKIDNEY CORP. PROK · Entity 5181	ConversionCommon Units in ProKidney Holdings, LLC · Derivative	675,235	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001193125-26-336856 · ownership.xml · derivative · entry 6 Pereira Brian JG · CIK 0001298146 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Brian J. G. Pereira 2012 Irrevocable Trust Disclosed balance after: 0 Underlying: Class A Common Stock · 675,235 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney LP. The Common Units do not expire. F3 · derivative.expiration_date: The Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney LP. The Common Units do not expire. Read SEC document
August 04, 2026 Filed Aug 6, 2026 12:09 UTC	PROKIDNEY CORP. PROK · Entity 5181	ConversionClass B Common Stock · Derivative	675,235	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001193125-26-336856 · ownership.xml · derivative · entry 5 Pereira Brian JG · CIK 0001298146 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Brian J. G. Pereira 2012 Irrevocable Trust Disclosed balance after: 0 Underlying: Class A Common Stock · 675,235 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The shares of Class B Common Stock and the Common Units in ProKidney Holdings LLC (a "Common Unit") are paired securities. At the election of the reporting person and subject to the limitations set forth in the Amended and Restated Exchange Agreement, dated as of July 1, 2025, and the Second Amended and Restated Limited Liability Company Agreement of ProKidney Holdings, LLC, each share of Class B Common Stock, together with a paired Common Unit, may be exchanged for a share of Class A Common stock on a one-for-one basis. F2 · derivative.exercise_date: The shares of Class B Common Stock were received pursuant to the terms of the Business Combination Agreement by and between the Issuer (formerly known as Social Capital Suvretta Holdings Corp. III) and ProKidney LP, dated as of January 18, 2022 (the "Business Combination Agreement"), in exchange for historical interests held by the reporting person in ProKidney LP. The shares of Class B Common Stock do not expire. F2 · derivative.expiration_date: The shares of Class B Common Stock were received pursuant to the terms of the Business Combination Agreement by and between the Issuer (formerly known as Social Capital Suvretta Holdings Corp. III) and ProKidney LP, dated as of January 18, 2022 (the "Business Combination Agreement"), in exchange for historical interests held by the reporting person in ProKidney LP. The shares of Class B Common Stock do not expire. Read SEC document
August 04, 2026 Filed Aug 6, 2026 12:09 UTC	PROKIDNEY CORP. PROK · Entity 5181	ConversionCommon Units in ProKidney Holdings, LLC · Derivative	81,929	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001193125-26-336856 · ownership.xml · derivative · entry 4 Pereira Brian JG · CIK 0001298146 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 81,929 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney LP. The Common Units do not expire. F3 · derivative.expiration_date: The Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney LP. The Common Units do not expire. Read SEC document
August 04, 2026 Filed Aug 6, 2026 12:09 UTC	PROKIDNEY CORP. PROK · Entity 5181	ConversionClass B Common Stock · Derivative	81,929	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001193125-26-336856 · ownership.xml · derivative · entry 3 Pereira Brian JG · CIK 0001298146 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 81,929 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The shares of Class B Common Stock and the Common Units in ProKidney Holdings LLC (a "Common Unit") are paired securities. At the election of the reporting person and subject to the limitations set forth in the Amended and Restated Exchange Agreement, dated as of July 1, 2025, and the Second Amended and Restated Limited Liability Company Agreement of ProKidney Holdings, LLC, each share of Class B Common Stock, together with a paired Common Unit, may be exchanged for a share of Class A Common stock on a one-for-one basis. F2 · derivative.exercise_date: The shares of Class B Common Stock were received pursuant to the terms of the Business Combination Agreement by and between the Issuer (formerly known as Social Capital Suvretta Holdings Corp. III) and ProKidney LP, dated as of January 18, 2022 (the "Business Combination Agreement"), in exchange for historical interests held by the reporting person in ProKidney LP. The shares of Class B Common Stock do not expire. F2 · derivative.expiration_date: The shares of Class B Common Stock were received pursuant to the terms of the Business Combination Agreement by and between the Issuer (formerly known as Social Capital Suvretta Holdings Corp. III) and ProKidney LP, dated as of January 18, 2022 (the "Business Combination Agreement"), in exchange for historical interests held by the reporting person in ProKidney LP. The shares of Class B Common Stock do not expire. Read SEC document
August 04, 2026 Filed Aug 6, 2026 12:09 UTC	PROKIDNEY CORP. PROK · Entity 5181	ConversionClass A Common Stock	675,235	$0.00	$0.00	Disclosure SEC source: 0001193125-26-336856 · ownership.xml · nonDerivative · entry 2 Pereira Brian JG · CIK 0001298146 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Brian J. G. Pereira 2012 Irrevocable Trust Disclosed balance after: 675,235 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 04, 2026 Filed Aug 6, 2026 12:09 UTC	PROKIDNEY CORP. PROK · Entity 5181	ConversionClass A Common Stock	81,929	$0.00	$0.00	Disclosure SEC source: 0001193125-26-336856 · ownership.xml · nonDerivative · entry 1 Pereira Brian JG · CIK 0001298146 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,929 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 11, 2026 Filed Jun 11, 2026 20:40 UTC	KalVista Pharmaceuticals, Inc. KALV · Entity 39180	Disposition to issuerStock Option (Right to Buy) · Derivative	30,000	Not disclosed Strike: $12.05	Not disclosed	Disclosure SEC source: 0001298146-26-000002 · form4-06112026_080609.xml · derivative · entry 7 Pereira Brian JG · CIK 0001298146 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2035-09-30 F1 · kind: The securities were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2026 (the "Merger Agreement"), by and among KalVista Pharmaceuticals, Inc., a Delaware corporation (the "Issuer" or the "Company"), Chiesi Farmaceutici S.p.A., an Italian societa per azioni ("Parent"), and Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Company Common Stock"), for a price per share of $27.00 (the "Merger Consideration"), without interest, less any applicable tax withholding. Effective as of June 11, 2026, Merger Sub merged with and into the Company with the Company surviving the Merger as a wholly owned subsidiary of the Parent (the "Merger"). F3 · price: Pursuant to the terms of the Merger Agreement, each option to purchase shares of Company Common Stock ("Company Option") that was outstanding and unexercised immediately prior to the effective time of the Merger (the "Effective Time") and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and converted into the right of the holder thereof to receive a cash payment (without interest) equal to the product of (A) the excess of (x) the Merger Consideration over (y) the per share exercise price of such Company Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time. Each Company Option that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration payable in respect thereof. F4 · derivative.exercise_date: The option vests over a 12 month period: 1/12th on November 1, 2025, after which 1/12th of the total shares vest monthly, subject to continued service through each vesting date. Read SEC document
June 11, 2026 Filed Jun 11, 2026 20:40 UTC	KalVista Pharmaceuticals, Inc. KALV · Entity 39180	Disposition to issuerStock Option (Right to Buy) · Derivative	10,000	Not disclosed Strike: $11.54	Not disclosed	Disclosure SEC source: 0001298146-26-000002 · form4-06112026_080609.xml · derivative · entry 6 Pereira Brian JG · CIK 0001298146 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2034-10-02 F1 · kind: The securities were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2026 (the "Merger Agreement"), by and among KalVista Pharmaceuticals, Inc., a Delaware corporation (the "Issuer" or the "Company"), Chiesi Farmaceutici S.p.A., an Italian societa per azioni ("Parent"), and Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Company Common Stock"), for a price per share of $27.00 (the "Merger Consideration"), without interest, less any applicable tax withholding. Effective as of June 11, 2026, Merger Sub merged with and into the Company with the Company surviving the Merger as a wholly owned subsidiary of the Parent (the "Merger"). F3 · price: Pursuant to the terms of the Merger Agreement, each option to purchase shares of Company Common Stock ("Company Option") that was outstanding and unexercised immediately prior to the effective time of the Merger (the "Effective Time") and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and converted into the right of the holder thereof to receive a cash payment (without interest) equal to the product of (A) the excess of (x) the Merger Consideration over (y) the per share exercise price of such Company Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time. Each Company Option that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration payable in respect thereof. F2 · derivative.exercise_date: The option is fully vested. Read SEC document
June 11, 2026 Filed Jun 11, 2026 20:40 UTC	KalVista Pharmaceuticals, Inc. KALV · Entity 39180	Disposition to issuerStock Option (Right to Buy) · Derivative	10,000	Not disclosed Strike: $10.08	Not disclosed	Disclosure SEC source: 0001298146-26-000002 · form4-06112026_080609.xml · derivative · entry 5 Pereira Brian JG · CIK 0001298146 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2033-09-25 F1 · kind: The securities were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2026 (the "Merger Agreement"), by and among KalVista Pharmaceuticals, Inc., a Delaware corporation (the "Issuer" or the "Company"), Chiesi Farmaceutici S.p.A., an Italian societa per azioni ("Parent"), and Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Company Common Stock"), for a price per share of $27.00 (the "Merger Consideration"), without interest, less any applicable tax withholding. Effective as of June 11, 2026, Merger Sub merged with and into the Company with the Company surviving the Merger as a wholly owned subsidiary of the Parent (the "Merger"). F3 · price: Pursuant to the terms of the Merger Agreement, each option to purchase shares of Company Common Stock ("Company Option") that was outstanding and unexercised immediately prior to the effective time of the Merger (the "Effective Time") and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and converted into the right of the holder thereof to receive a cash payment (without interest) equal to the product of (A) the excess of (x) the Merger Consideration over (y) the per share exercise price of such Company Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time. Each Company Option that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration payable in respect thereof. F2 · derivative.exercise_date: The option is fully vested. Read SEC document
June 11, 2026 Filed Jun 11, 2026 20:40 UTC	KalVista Pharmaceuticals, Inc. KALV · Entity 39180	Disposition to issuerStock Option (Right to Buy) · Derivative	10,000	Not disclosed Strike: $4.53	Not disclosed	Disclosure SEC source: 0001298146-26-000002 · form4-06112026_080609.xml · derivative · entry 4 Pereira Brian JG · CIK 0001298146 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2032-10-12 F1 · kind: The securities were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2026 (the "Merger Agreement"), by and among KalVista Pharmaceuticals, Inc., a Delaware corporation (the "Issuer" or the "Company"), Chiesi Farmaceutici S.p.A., an Italian societa per azioni ("Parent"), and Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Company Common Stock"), for a price per share of $27.00 (the "Merger Consideration"), without interest, less any applicable tax withholding. Effective as of June 11, 2026, Merger Sub merged with and into the Company with the Company surviving the Merger as a wholly owned subsidiary of the Parent (the "Merger"). F3 · price: Pursuant to the terms of the Merger Agreement, each option to purchase shares of Company Common Stock ("Company Option") that was outstanding and unexercised immediately prior to the effective time of the Merger (the "Effective Time") and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and converted into the right of the holder thereof to receive a cash payment (without interest) equal to the product of (A) the excess of (x) the Merger Consideration over (y) the per share exercise price of such Company Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time. Each Company Option that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration payable in respect thereof. F2 · derivative.exercise_date: The option is fully vested. Read SEC document
June 11, 2026 Filed Jun 11, 2026 20:40 UTC	KalVista Pharmaceuticals, Inc. KALV · Entity 39180	Disposition to issuerStock Option (Right to Buy) · Derivative	10,000	Not disclosed Strike: $17.45	Not disclosed	Disclosure SEC source: 0001298146-26-000002 · form4-06112026_080609.xml · derivative · entry 3 Pereira Brian JG · CIK 0001298146 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2031-09-29 F1 · kind: The securities were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2026 (the "Merger Agreement"), by and among KalVista Pharmaceuticals, Inc., a Delaware corporation (the "Issuer" or the "Company"), Chiesi Farmaceutici S.p.A., an Italian societa per azioni ("Parent"), and Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Company Common Stock"), for a price per share of $27.00 (the "Merger Consideration"), without interest, less any applicable tax withholding. Effective as of June 11, 2026, Merger Sub merged with and into the Company with the Company surviving the Merger as a wholly owned subsidiary of the Parent (the "Merger"). F3 · price: Pursuant to the terms of the Merger Agreement, each option to purchase shares of Company Common Stock ("Company Option") that was outstanding and unexercised immediately prior to the effective time of the Merger (the "Effective Time") and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and converted into the right of the holder thereof to receive a cash payment (without interest) equal to the product of (A) the excess of (x) the Merger Consideration over (y) the per share exercise price of such Company Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time. Each Company Option that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration payable in respect thereof. F2 · derivative.exercise_date: The option is fully vested. Read SEC document
June 11, 2026 Filed Jun 11, 2026 20:40 UTC	KalVista Pharmaceuticals, Inc. KALV · Entity 39180	Disposition to issuerStock Option (Right to Buy) · Derivative	7,000	Not disclosed Strike: $12.88	Not disclosed	Disclosure SEC source: 0001298146-26-000002 · form4-06112026_080609.xml · derivative · entry 2 Pereira Brian JG · CIK 0001298146 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,000 shares Expires 2030-09-30 F1 · kind: The securities were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2026 (the "Merger Agreement"), by and among KalVista Pharmaceuticals, Inc., a Delaware corporation (the "Issuer" or the "Company"), Chiesi Farmaceutici S.p.A., an Italian societa per azioni ("Parent"), and Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Company Common Stock"), for a price per share of $27.00 (the "Merger Consideration"), without interest, less any applicable tax withholding. Effective as of June 11, 2026, Merger Sub merged with and into the Company with the Company surviving the Merger as a wholly owned subsidiary of the Parent (the "Merger"). F3 · price: Pursuant to the terms of the Merger Agreement, each option to purchase shares of Company Common Stock ("Company Option") that was outstanding and unexercised immediately prior to the effective time of the Merger (the "Effective Time") and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and converted into the right of the holder thereof to receive a cash payment (without interest) equal to the product of (A) the excess of (x) the Merger Consideration over (y) the per share exercise price of such Company Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time. Each Company Option that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration payable in respect thereof. F2 · derivative.exercise_date: The option is fully vested. Read SEC document
June 11, 2026 Filed Jun 11, 2026 20:40 UTC	KalVista Pharmaceuticals, Inc. KALV · Entity 39180	Disposition to issuerStock Option (Right to Buy) · Derivative	14,000	Not disclosed Strike: $17.95	Not disclosed	Disclosure SEC source: 0001298146-26-000002 · form4-06112026_080609.xml · derivative · entry 1 Pereira Brian JG · CIK 0001298146 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,000 shares Expires 2029-01-31 F1 · kind: The securities were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2026 (the "Merger Agreement"), by and among KalVista Pharmaceuticals, Inc., a Delaware corporation (the "Issuer" or the "Company"), Chiesi Farmaceutici S.p.A., an Italian societa per azioni ("Parent"), and Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Company Common Stock"), for a price per share of $27.00 (the "Merger Consideration"), without interest, less any applicable tax withholding. Effective as of June 11, 2026, Merger Sub merged with and into the Company with the Company surviving the Merger as a wholly owned subsidiary of the Parent (the "Merger"). F3 · price: Pursuant to the terms of the Merger Agreement, each option to purchase shares of Company Common Stock ("Company Option") that was outstanding and unexercised immediately prior to the effective time of the Merger (the "Effective Time") and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and converted into the right of the holder thereof to receive a cash payment (without interest) equal to the product of (A) the excess of (x) the Merger Consideration over (y) the per share exercise price of such Company Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time. Each Company Option that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration payable in respect thereof. F2 · derivative.exercise_date: The option is fully vested. Read SEC document
May 28, 2026 Filed May 29, 2026 20:03 UTC	PROKIDNEY CORP. PROK · Entity 5181	GrantDirector stock option (right to buy) · Derivative	135,000	$0.00 Strike: $1.81	$0.00	Disclosure SEC source: 0001193125-26-248215 · ownership.xml · derivative · entry 1 Pereira Brian JG · CIK 0001298146 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,000 Underlying: Class A Common Stock · 135,000 shares Expires 2036-05-28 F1 · shares: These options were granted under the Issuer's non-employee director compensation policy. F2 · derivative.exercise_date: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting. Read SEC document
November 13, 2025 Filed Nov 14, 2025 21:07 UTC	PROKIDNEY CORP. PROK · Entity 5181	SaleClass A Common Stock	54,333	$2.37	$128,769.21	Disclosure SEC source: 0001193125-25-282922 · ownership.xml · nonDerivative · entry 4 Pereira Brian JG · CIK 0001298146 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Brian J. G. Pereira 2004 Trust Disclosed balance after: 0 F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.25 to $2.66, inclusive. The reporting person undertakes to provide to ProKidney Corp., any security holder of ProKidney Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote Read SEC document
November 13, 2025 Filed Nov 14, 2025 21:07 UTC	PROKIDNEY CORP. PROK · Entity 5181	SaleClass A Common Stock	447,803	$2.37	$1,061,293.11	Disclosure SEC source: 0001193125-25-282922 · ownership.xml · nonDerivative · entry 3 Pereira Brian JG · CIK 0001298146 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Brian J. G. Pereira 2012 Irrevocable Trust Disclosed balance after: 0 F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.25 to $2.66, inclusive. The reporting person undertakes to provide to ProKidney Corp., any security holder of ProKidney Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote Read SEC document
November 12, 2025 Filed Nov 14, 2025 21:07 UTC	PROKIDNEY CORP. PROK · Entity 5181	SaleClass A Common Stock	27,595	$2.72	$75,152.22	Disclosure SEC source: 0001193125-25-282922 · ownership.xml · nonDerivative · entry 2 Pereira Brian JG · CIK 0001298146 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Brian J. G. Pereira 2004 Trust Disclosed balance after: 54,333 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.70 to $2.88, inclusive. The reporting person undertakes to provide to ProKidney Corp., any security holder of ProKidney Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
November 12, 2025 Filed Nov 14, 2025 21:07 UTC	PROKIDNEY CORP. PROK · Entity 5181	SaleClass A Common Stock	227,431	$2.72	$619,362.84	Disclosure SEC source: 0001193125-25-282922 · ownership.xml · nonDerivative · entry 1 Pereira Brian JG · CIK 0001298146 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Brian J. G. Pereira 2012 Irrevocable Trust Disclosed balance after: 447,803 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.70 to $2.88, inclusive. The reporting person undertakes to provide to ProKidney Corp., any security holder of ProKidney Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
October 01, 2025 Filed Oct 2, 2025 22:31 UTC	KalVista Pharmaceuticals, Inc. KALV · Entity 39180	GrantStock Option (right to buy) · Derivative	30,000	$0.00 Strike: $12.05	$0.00	Disclosure SEC source: 0001298146-25-000004 · form4-10022025_101026.xml · derivative · entry 1 Pereira Brian JG · CIK 0001298146 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-09-30 F1 · derivative.exercise_date: The option vests over a 12 month period: 1/12th on November 1, 2025, after which 1/12th of the total shares vest monthly, subject to continued service through each vesting date. Read SEC document
May 29, 2025 Filed Jun 2, 2025 20:14 UTC	PROKIDNEY CORP. PROK · Entity 5181	GrantDirector stock option (right to buy) · Derivative	125,862	$0.00 Strike: $0.72	$0.00	Disclosure SEC source: 0000950170-25-080269 · ownership.xml · derivative · entry 1 Pereira Brian JG · CIK 0001298146 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,862 Underlying: Class A Ordinary Shares · 125,862 shares Expires 2035-05-29 F1 · shares: These options were granted under the Issuer's non-employee director compensation policy. F2 · derivative.exercise_date: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting. Read SEC document
February 04, 2025 Filed Feb 6, 2025 21:05 UTC	PROKIDNEY CORP. PROK · Entity 5181	ConversionCommon Units in ProKidney LP · Derivative	675,234	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000950170-25-015369 · ownership.xml · derivative · entry 6 Pereira Brian JG · CIK 0001298146 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Brian J. G. Pereira 2012 Irrevocable Trust Disclosed balance after: 675,235 Underlying: Class A Ordinary Shares · 675,234 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney LP. The Common Units do not expire. F3 · derivative.expiration_date: The Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney LP. The Common Units do not expire. Read SEC document
February 04, 2025 Filed Feb 6, 2025 21:05 UTC	PROKIDNEY CORP. PROK · Entity 5181	ConversionClass B Ordinary Shares · Derivative	675,234	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000950170-25-015369 · ownership.xml · derivative · entry 5 Pereira Brian JG · CIK 0001298146 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Brian J. G. Pereira 2012 Irrevocable Trust Disclosed balance after: 675,235 Underlying: Class A Ordinary Shares · 675,234 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Class B Ordinary Shares and the Common Units in ProKidney LP (a "Common Unit") are paired securities. At the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement (each filed as an Issuer's Annual Report on Form 10-K filed on March 22, 2024), each Class B Ordinary Share, together with a paired Common Unit, may be exchanged for Class A Ordinary Shares on a one-for-one basis. F2 · derivative.exercise_date: The Class B Ordinary Shares were received pursuant to the terms of the Business Combination Agreement by and between the Issuer and ProKidney LP, dated as of January 18, 2022 (the "Business Combination Agreement"), in exchange for historical interests held by the reporting person in ProKidney LP. The Class B Ordinary Shares do not expire. F2 · derivative.expiration_date: The Class B Ordinary Shares were received pursuant to the terms of the Business Combination Agreement by and between the Issuer and ProKidney LP, dated as of January 18, 2022 (the "Business Combination Agreement"), in exchange for historical interests held by the reporting person in ProKidney LP. The Class B Ordinary Shares do not expire. Read SEC document
February 04, 2025 Filed Feb 6, 2025 21:05 UTC	PROKIDNEY CORP. PROK · Entity 5181	ConversionCommon Units in ProKidney LP · Derivative	81,928	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000950170-25-015369 · ownership.xml · derivative · entry 4 Pereira Brian JG · CIK 0001298146 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,929 Underlying: Class A Ordinary Shares · 81,928 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney LP. The Common Units do not expire. F3 · derivative.expiration_date: The Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney LP. The Common Units do not expire. Read SEC document
February 04, 2025 Filed Feb 6, 2025 21:05 UTC	PROKIDNEY CORP. PROK · Entity 5181	ConversionClass B Ordinary Shares · Derivative	81,928	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000950170-25-015369 · ownership.xml · derivative · entry 3 Pereira Brian JG · CIK 0001298146 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,929 Underlying: Class A Ordinary Shares · 81,928 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Class B Ordinary Shares and the Common Units in ProKidney LP (a "Common Unit") are paired securities. At the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement (each filed as an Issuer's Annual Report on Form 10-K filed on March 22, 2024), each Class B Ordinary Share, together with a paired Common Unit, may be exchanged for Class A Ordinary Shares on a one-for-one basis. F2 · derivative.exercise_date: The Class B Ordinary Shares were received pursuant to the terms of the Business Combination Agreement by and between the Issuer and ProKidney LP, dated as of January 18, 2022 (the "Business Combination Agreement"), in exchange for historical interests held by the reporting person in ProKidney LP. The Class B Ordinary Shares do not expire. F2 · derivative.expiration_date: The Class B Ordinary Shares were received pursuant to the terms of the Business Combination Agreement by and between the Issuer and ProKidney LP, dated as of January 18, 2022 (the "Business Combination Agreement"), in exchange for historical interests held by the reporting person in ProKidney LP. The Class B Ordinary Shares do not expire. Read SEC document
February 04, 2025 Filed Feb 6, 2025 21:05 UTC	PROKIDNEY CORP. PROK · Entity 5181	ConversionClass A Ordinary Shares	675,234	$0.00	$0.00	Disclosure SEC source: 0000950170-25-015369 · ownership.xml · nonDerivative · entry 2 Pereira Brian JG · CIK 0001298146 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Brian J. G. Pereira 2012 Irrevocable Trust Disclosed balance after: 675,234 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 04, 2025 Filed Feb 6, 2025 21:05 UTC	PROKIDNEY CORP. PROK · Entity 5181	ConversionClass A Ordinary Shares	81,928	$0.00	$0.00	Disclosure SEC source: 0000950170-25-015369 · ownership.xml · nonDerivative · entry 1 Pereira Brian JG · CIK 0001298146 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,928 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
October 03, 2024 Filed Oct 4, 2024 20:08 UTC	KalVista Pharmaceuticals, Inc. KALV · Entity 39180	GrantStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $11.54	$0.00	Disclosure SEC source: 0001415889-24-024751 · form4-10042024_081011.xml · derivative · entry 1 Pereira Brian JG · CIK 0001298146 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-10-02 F1 · derivative.exercise_date: The option vests over a 12-month period: 1/12th on November 3, 2024, after which 1/12th of the total shares vest monthly, subject to continued service through each vesting date. Read SEC document
May 30, 2024 Filed Jun 3, 2024 20:32 UTC	PROKIDNEY CORP. PROK · Entity 5181	GrantDirector stock option (right to buy) · Derivative	62,558	$0.00 Strike: $4.20	$0.00	Disclosure SEC source: 0000950170-24-068043 · ownership.xml · derivative · entry 1 Pereira Brian JG · CIK 0001298146 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,558 Underlying: Class A Ordinary Shares · 62,558 shares Expires 2034-05-30 F1 · shares: These options were granted under the Issuer's non-employee director compensation policy. F2 · derivative.exercise_date: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting. Read SEC document
September 26, 2023 Filed Sep 28, 2023 20:53 UTC	KalVista Pharmaceuticals, Inc. KALV · Entity 39180	GrantStock Option (right to buy) · Derivative	10,000	$0.00 Strike: $10.08	$0.00	Disclosure SEC source: 0001209191-23-050754 · doc4.xml · derivative · entry 1 Pereira Brian JG · CIK 0001298146 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2033-09-25 F1 · derivative.exercise_date: The option vests over a 12 month period: 1/12th on October 26, 2023, after which 1/12th of the total shares vest monthly, subject to continued service through each vesting date. Read SEC document
June 29, 2023 Filed Jul 3, 2023 13:18 UTC	PROKIDNEY CORP. PROK · Entity 5181	GrantDirector stock option (right to buy) · Derivative	48,128	$0.00 Strike: $10.56	$0.00	Disclosure SEC source: 0001209191-23-040424 · doc4.xml · derivative · entry 1 Pereira Brian JG · CIK 0001298146 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,128 Underlying: Class A Ordinary Shares · 48,128 shares Expires 2033-06-29 F1 · shares: These options were granted under the Issuer's non-employee director compensation policy. F2 · derivative.exercise_date: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting. Read SEC document
October 13, 2022 Filed Oct 17, 2022 22:35 UTC	KalVista Pharmaceuticals, Inc. KALV · Entity 39180	GrantEmployee Stock Option (right to buy) · Derivative	10,000	$0.00 Strike: $4.53	$0.00	Disclosure SEC source: 0001209191-22-053876 · doc4.xml · derivative · entry 1 Pereira Brian JG · CIK 0001298146 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-10-12 F1 · derivative.exercise_date: The option vests over a 12 month period: 1/12th on October 13, 2022, after which 1/12th of the total shares vest monthly, subject to continued service through each vesting date. Read SEC document
July 11, 2022 Filed Jul 14, 2022 01:32 UTC	PROKIDNEY CORP. PROK · Entity 5181	GrantCommon Units in ProKidney LP · Derivative	1,514,326	$0.00	$0.00	Disclosure SEC source: 0000950103-22-012376 · dp177030_4-pereira.xml · derivative · entry 2 Pereira Brian JG · CIK 0001298146 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,514,326 Underlying: Class A Ordinary Shares · 1,514,326 shares Expires not disclosed F3 · security: Each Common Unit may, at the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement, be exchanged, together with the paired Class B Ordinary Share, into a Class A Ordinary Share on a one-for-one basis. F3 · derivative.exercise_price: Each Common Unit may, at the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement, be exchanged, together with the paired Class B Ordinary Share, into a Class A Ordinary Share on a one-for-one basis. F4 · derivative.exercise_price: These 1,350,469 Common Units and 163,857 Restricted Common Units of ProKidney Equity LLC that upon vesting will settle in Common Units ("PMEL RCUs") were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney. The PMEL RCUs vest in installments over a period through January 17, 2025. The Common Units and the PMEL RCUs do not expire. F4 · derivative.exercise_date: These 1,350,469 Common Units and 163,857 Restricted Common Units of ProKidney Equity LLC that upon vesting will settle in Common Units ("PMEL RCUs") were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney. The PMEL RCUs vest in installments over a period through January 17, 2025. The Common Units and the PMEL RCUs do not expire. F4 · derivative.expiration_date: These 1,350,469 Common Units and 163,857 Restricted Common Units of ProKidney Equity LLC that upon vesting will settle in Common Units ("PMEL RCUs") were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney. The PMEL RCUs vest in installments over a period through January 17, 2025. The Common Units and the PMEL RCUs do not expire. Read SEC document
July 11, 2022 Filed Jul 14, 2022 01:32 UTC	PROKIDNEY CORP. PROK · Entity 5181	GrantClass B Ordinary Shares · Derivative	1,514,326	$0.00	$0.00	Disclosure SEC source: 0000950103-22-012376 · dp177030_4-pereira.xml · derivative · entry 1 Pereira Brian JG · CIK 0001298146 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,514,326 Underlying: Class A Ordinary Shares · 1,514,326 shares Expires not disclosed F1 · derivative.exercise_price: Each Class B Ordinary Share has no economic rights but entitles the reporting person to vote on all matters on which shareholders of the issuer vote and may, at the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement (each as defined and as described in the issuer's Definitive Proxy Statement filed with the Securities and Exchange Commission on June 10, 2022), be exchanged, together with the paired Common Unit in ProKidney LP ("ProKidney") (a "Common Unit"), for a Class A Ordinary Share on a one-for-one basis. F2 · derivative.exercise_price: These 1,350,469 Class B Ordinary Shares and 163,857 Restricted Stock Rights in respect of Class B Ordinary Shares ("Class B PMEL RSRs") were received pursuant to the terms of the Business Combination Agreement by and between the issuer and ProKidney dated as of January 18, 2022 (the "Business Combination Agreement") in exchange for historical interests held by the reporting person in ProKidney. The Class B PMEL RSRs vest in installments over a period through January 17, 2025, and upon vesting are immediately settled as Class B Ordinary Shares. The Class B Ordinary Shares and Class B PMEL RSRs do not expire. F2 · derivative.exercise_date: These 1,350,469 Class B Ordinary Shares and 163,857 Restricted Stock Rights in respect of Class B Ordinary Shares ("Class B PMEL RSRs") were received pursuant to the terms of the Business Combination Agreement by and between the issuer and ProKidney dated as of January 18, 2022 (the "Business Combination Agreement") in exchange for historical interests held by the reporting person in ProKidney. The Class B PMEL RSRs vest in installments over a period through January 17, 2025, and upon vesting are immediately settled as Class B Ordinary Shares. The Class B Ordinary Shares and Class B PMEL RSRs do not expire. F2 · derivative.expiration_date: These 1,350,469 Class B Ordinary Shares and 163,857 Restricted Stock Rights in respect of Class B Ordinary Shares ("Class B PMEL RSRs") were received pursuant to the terms of the Business Combination Agreement by and between the issuer and ProKidney dated as of January 18, 2022 (the "Business Combination Agreement") in exchange for historical interests held by the reporting person in ProKidney. The Class B PMEL RSRs vest in installments over a period through January 17, 2025, and upon vesting are immediately settled as Class B Ordinary Shares. The Class B Ordinary Shares and Class B PMEL RSRs do not expire. Read SEC document
September 30, 2021 Filed Oct 1, 2021 20:55 UTC	KalVista Pharmaceuticals, Inc. KALV · Entity 39180	GrantDirector Stock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $17.45	$0.00	Disclosure SEC source: 0001209191-21-058486 · doc4.xml · derivative · entry 1 Pereira Brian JG · CIK 0001298146 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-09-29 F1 · derivative.exercise_date: The option vests over a 12 month period: 1/12th on October 30, 2021, after which 1/12th of the total shares vest monthly, subject to continued service through each vesting date. Read SEC document
October 01, 2020 Filed Oct 3, 2020 00:36 UTC	KalVista Pharmaceuticals, Inc. KALV · Entity 39180	GrantDirector Stock Option (right to buy) · Derivative	7,000	$0.00 Strike: $12.88	$0.00	Disclosure SEC source: 0001209191-20-053395 · doc4.xml · derivative · entry 1 Pereira Brian JG · CIK 0001298146 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2030-09-30 F1 · derivative.exercise_date: The option vests over a 12 month period: 1/12th on November 1, 2020, after which 1/12th of the total shares vest monthly, subject to continued service through each vesting date. Read SEC document
April 15, 2020 Filed Apr 17, 2020 23:03 UTC	ABEONA THERAPEUTICS INC. ABEO · Entity 5808	GrantEmployee Stock Option (right to buy) · Derivative	930,000	$0.00 Strike: $2.50	$0.00	Disclosure SEC source: 0001493152-20-006669 · ownership.xml · derivative · entry 1 Pereira Brian JG · CIK 0001298146 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 930,000 Underlying: Common Stock · 930,000 shares Expires 2030-04-15 F1 · derivative.exercise_date: The options will vest 25% on April 15, 2021, and in 36 equal monthly installments thereafter. Read SEC document
February 01, 2019 Filed Feb 5, 2019 22:41 UTC	KalVista Pharmaceuticals, Inc. KALV · Entity 39180	GrantDirector Stock Option (Right to Buy) · Derivative	14,000	$0.00 Strike: $17.95	$0.00	Disclosure SEC source: 0001567619-19-002402 · doc1.xml · derivative · entry 1 Pereira Brian JG · CIK 0001298146 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2029-01-31 F1 · derivative.exercise_date: The option vests over a 3 year period: 1/36th vests on March 1, 2019, after which 1/36th of the total shares vest monthly, subject to reporting person's continued service through each vesting date. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.